• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2025 Results on July 17

    7/2/25 4:15:00 PM ET
    $ELV
    Medical Specialities
    Health Care
    Get the next $ELV alert in real time by email

    Elevance Health (NYSE:ELV) will release second quarter 2025 financial results on July 17, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers:

    • 888-947-9963 - Access Code - 3972058 (Domestic)
    • 312-470-0178 - Access Code - 3972058 (International)
    • 866-511-1890 - No Access Code (Domestic Replay)
    • 203-369-1945 - No Access Code (International Replay)

    The replay will be available from 11:30 a.m. EDT on July 17, 2025, until the end of the day on August 15, 2025. The call will also be available through a live webcast at www.elevancehealth.com under the "Investors" link. You may also access the webcast here. A webcast replay will be available following the call.

    About Elevance Health

    Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health's companies serve over 110 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, home health, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250702679165/en/

    Investor Relations:

    Nathan Rich

    [email protected]

    Media Relations:

    Leslie Porras

    [email protected]

    Get the next $ELV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELV

    DatePrice TargetRatingAnalyst
    7/21/2025Buy → Hold
    Argus
    7/18/2025$310.00Outperform → Market Perform
    Leerink Partners
    4/15/2025$529.00Outperform → Neutral
    Robert W. Baird
    3/17/2025$450.00Hold → Buy
    Argus
    1/22/2025$520.00 → $440.00Overweight → Equal-Weight
    Stephens
    10/18/2024Buy → Hold
    Argus
    7/18/2024$646.00 → $530.00Buy → Neutral
    BofA Securities
    6/24/2024$643.00Overweight
    Morgan Stanley
    More analyst ratings

    $ELV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Boudreaux Gail bought $2,438,951 worth of shares (8,500 units at $286.94), increasing direct ownership by 6% to 151,020 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/18/25 1:42:51 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    SEC Filings

    View All

    Elevance Health Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Elevance Health, Inc. (0001156039) (Filer)

    7/28/25 4:38:34 PM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Elevance Health Inc.

    10-Q - Elevance Health, Inc. (0001156039) (Filer)

    7/17/25 3:09:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Elevance Health, Inc. (0001156039) (Filer)

    7/17/25 6:03:40 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Collis Steven H was granted 639 shares (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    8/5/25 4:18:25 PM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form 3 filed by new insider Collis Steven H

    3 - Elevance Health, Inc. (0001156039) (Issuer)

    8/1/25 4:31:24 PM ET
    $ELV
    Medical Specialities
    Health Care

    President and CEO Boudreaux Gail bought $2,438,951 worth of shares (8,500 units at $286.94), increasing direct ownership by 6% to 151,020 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/18/25 1:42:51 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elevance Health downgraded by Argus

    Argus downgraded Elevance Health from Buy to Hold

    7/21/25 8:26:59 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Elevance Health from Outperform to Market Perform and set a new price target of $310.00

    7/18/25 8:10:27 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Elevance Health from Outperform to Neutral and set a new price target of $529.00

    4/15/25 9:24:40 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elevance Health and National Association of Community Health Centers Partnership Integrates Food as Medicine With Primary Care

    Trained providers to screen, enroll eligible members to receive evidence-based nutrition and dietary services. Elevance Health and the National Association of Community Health Centers (NACHC) are proud to announce the integration of Food as Medicine (FAM) programming with primary care Community Health Centers (CHCs). This milestone - built on a shared commitment to whole health and community-centered innovation - marks a transformative step forward in addressing food/nutrition insecurity and diet-related chronic conditions through clinical integration. A Whole Health Approach to Redefining Primary Care This initiative expands Elevance Health's existing regional Nourished Well program

    8/18/25 9:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Board Welcomes Steve Collis as New Director, Reflecting Ongoing Commitment to Governance Excellence

    The board of directors of Elevance Health (NYSE:ELV) announced today that Steve Collis, a highly regarded global healthcare executive, will be joining the company's board, effective August 1. He will also serve on the board's Audit and Finance Committees, further enhancing the board's industry expertise and financial oversight capabilities. His addition is part of the board's ongoing commitment and structured approach to refresh its membership in support of the company's strategy, stakeholder needs, and the broader healthcare landscape. "Steve brings a distinguished record of leadership, transformation, and operational excellence. His insights will support our continued focus on deliverin

    7/28/25 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Study Finds Digital Asthma Program Significantly Improves Symptom Control in Adults

    Elevance Health and UC Irvine study underscores potential of digital health tools to reduce asthma burden across U.S. populations A groundbreaking clinical trial led by multidisciplinary researchers found that a digital asthma self-management (DASM) program significantly improved asthma symptom control in adults, with benefits sustained over 12 months. Program participants used everyday devices - like Apple Watch and iPhone – along with a tailored mobile app to help them manage their asthma. The findings represent some of the most compelling evidence to date supporting the use of digital health technologies in asthma care. The virtual, randomized, controlled and decentralized study was

    7/22/25 9:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Leadership Updates

    Live Leadership Updates

    View All

    Elevance Health Appoints Nathan Rich Vice President, Investor Relations

    Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe

    11/4/24 9:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Former Deputy Commissioner of New York State Department of Health Joins Sheppard Mullin

    Nationally Recognized Healthcare Policy Leader Adam Herbst Strengthens the Firm's Regulatory Capabilities for Clients Across the Post-Acute, Aging and Long-Term Care Sectors Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Adam S. Herbst has joined the firm as a healthcare partner in New York. Most recently, Herbst served as the New York State Department of Health's Deputy Commissioner for Aging and Long Term Care. He is the ninth healthcare partner to join the firm in 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030758975/en/Adam Herbst (Photo: Business Wire) In joining Sheppard Mullin's industry-l

    10/30/24 12:55:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Performant Financial Corporation Announces the Appointment of Dr. Shantanu Agrawal to Its Board of Directors

    Performant Financial Corporation (NASDAQ:PFMT) (Performant), primarily operating as Performant Healthcare Solutions, a leading provider of technology-enabled payment integrity, eligibility, and related analytics services, is proud to announce the appointment of Dr. Shantanu Agrawal, M.D. to its Board of Directors. Dr. Agrawal brings a wealth of expertise and experience in healthcare policy and payment integrity. As Chief Health Officer at Elevance Health (NYSE:ELV), Dr. Agrawal oversees the whole health strategy, including medical policy and clinical quality, as well as the community health strategy and Elevance Health Foundation. Prior to Elevance Health, Dr. Agrawal held numerous execut

    3/6/24 4:30:00 PM ET
    $ELV
    $PFMT
    Medical Specialities
    Health Care
    Other Consumer Services
    Consumer Discretionary

    $ELV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elevance Health Inc.

    SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)

    11/14/24 1:22:35 PM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Elevance Health Inc.

    SC 13G - Elevance Health, Inc. (0001156039) (Subject)

    2/14/24 10:02:59 AM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Elevance Health Inc.

    SC 13G - Elevance Health, Inc. (0001156039) (Subject)

    2/14/23 12:37:59 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Financials

    Live finance-specific insights

    View All

    Elevance Health Reports Second Quarter 2025 Results

    2Q 2025 operating revenue of $49.4 billion, up 14.3% from 2Q 2024 2Q 2025 diluted EPS1 of $7.72; adjusted diluted EPS2 of $8.84 Revising FY 2025 adjusted diluted EPS guidance to approximately $30.00 Returned $2.0 billion of capital to shareholders year-to-date Elevance Health, Inc. (NYSE:ELV) reported second quarter 2025 results. "In the second quarter, Elevance Health made meaningful progress in delivering an experience that is simple and personal to those we serve, while advancing our efforts to enhance efficiency across the healthcare system. We are updating our outlook to reflect elevated medical cost trends in ACA and slower rate alignment in Medicaid. While the exter

    7/17/25 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2025 Results on July 17

    Elevance Health (NYSE:ELV) will release second quarter 2025 financial results on July 17, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 866-511-1890 - No Access Code (Domestic Replay) 203-369-1945 - No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on July 17, 2025, until the end of the day on August 15, 2025. The call w

    7/2/25 4:15:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Reports First Quarter 2025 Results

    1Q 2025 operating revenue of $48.8 billion, up 15.4% from 1Q 2024 1Q 2025 adjusted operating gain1 of $3.3 billion, up 4.1% from 1Q 2024 1Q 2025 diluted EPS2 of $9.61; adjusted diluted EPS1 of $11.97 Reaffirm FY 2025 adjusted diluted EPS1 of $34.15 to $34.85 Returned $1.3 billion of capital to shareholders in 1Q 2025 Elevance Health, Inc. (NYSE:ELV) reported first quarter 2025 results. "At Elevance Health, our purpose—to improve the health of humanity—drives everything we do. In the first quarter, we made measurable progress reimagining the healthcare experience with personalized support, real-time digital solutions, and a whole-health model that improves outcomes and reduces co

    4/22/25 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care